Command Palette

Search for a command to run...

Clinical Trials · NCT05794581

A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

CompletedPhase 1Liraglutide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Carmot Therapeutics, Inc.
Enrollment
32
Start date
Mar 2023
Locations
1 site, United States
Primary endpoint
To assess area under the curve (AUC) in glucose metabolism during MMTT
View Liraglutide compound reference